Oric Pharmaceuticals, Inc. — Form D
Oric Pharmaceuticals, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-07-05. The offering totals $85.0M, of which $85.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-07-05
- Form: D
- Accession: 0001796280-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $85.0M
- Amount sold: $85.0M
- Investors: 12
- Date of first sale: 2023-06-27
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-485949
Issuer
- Name: Oric Pharmaceuticals, Inc.
- CIK: 0001796280
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
- Phone: (650) 388-5600
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Steve L Hoerter | Director | South San Francisco, CA |
| Lori L Kunkel | Director | South San Francisco, CA |
| Jacob M Chacko | Director | South San Francisco, CA |
| Jacob M Chacko | Executive Officer | South San Francisco, CA |
| Richard M Heyman | Director | South San Francisco, CA |
| Dominic M Piscitelli | Executive Officer | South San Francisco, CA |
| Angie L You | Director | South San Francisco, CA |
| Pratik M Multani | Executive Officer | South San Francisco, CA |
| Mardi C Dier | Director | South San Francisco, CA |
| Mardi M Dier | Director | South San Francisco, CA |
Other filings by this issuer (2)
More